2021 / 03

DOI: 10.47183/mes.2021.036

ORIGINAL RESEARCH

Experimental and clinical evaluation of mefloquine effectiveness against the infection caused by SARS-CoV-2

Filin KN, Gladkikh VD, Bykov VN
About authors

Federal State Unitary Enterprise Research & Production Center "Pharmaceutical Protection" of Federal Medical Biological Agency, Khimki, Moscow Region, Russia

Correspondence should be addressed: Vadim D. Gladkikh
Vaschutinskoe shosse, 11, g. Himki, Moskovskaja oblast, 141402; ur.relbmar@7002hcikdalg

About paper

Author contribution: Filin KN — study concept and design, manuscript writing; Gladkikh VD — manuscript writing and editing; Bykov VN — literature analysis, data acquisition and processing, manuscript writing.

Compliance with ethical standards: animal experiments were approved by the Bioethics Commission of RMC “Home of Pharmacy» (protocol № 3.71/20 dated December 23, 2020); all the procedures involving animals were performed in accordance with the Directive N 2010/63/EC of the European Parliament and of the Council of the European Union "On the Protection of Animals Used for Scientific Purposes" of September 22, 2010. The animals' housing and care complied with GOST R 53434-2009 (Principles of Good Laboratory Practice) and the Guidelines for Laboratory Animals (2010). The clinical trial was approved by the Ethics Commitees of the clinical centers of Burnasyan Federal Medical Biophysical Center of FMBA, Federal Clinical Center for High Medical Technologies of FMBA, Center for Specialized Medical Assistance and Medical Technologies of FMBA, National Medical Research Center for Otorhinolaryngology of FMBA; the trial was carried out in accordance with the Russian Federation Government Decree № 441 of April 3, 2020; the informed consent was obtained from all patients.

Received: 2021-07-21 Accepted: 2021-08-26 Published online: 2021-09-30
|
  1. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am J Chin Med. 2020; 48 (3): 737–762. DOI: 10.1142/S0192415X20500378.
  2. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18; 6: 16. DOI: 10.1038/s41421-020-0156-0.
  3. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28; 71 (15): 732–9. DOI: 10.1093/cid/ciaa237.
  4. Sweeney TR. The present status of malaria chemotherapy: Mefloquine, a novel antimalarial. Medicinal Research Reviews. 1981; 1 (3): 281–301. DOI: 10.1002/med.2610010304.
  5. Karbwang J, Na-Bangchang K. Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. Fundam Clin Pharmacol. 1994; 8 (6): 491–502. DOI: 10.1111/ j.1472-8206.1994.tb00830.x.
  6. Sun W, He S, Martínez-Romero C, et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Research. 2017 Jan; 137: 165–72. DOI: 10.1016/j.antiviral.2016.11.017.
  7. Balasubramanian A, Teramoto T, Kulkarni AA, Bhattacharjee AK, Padmanabhan R. Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antiviral Research. 2017; 137: 141–50. DOI: 10.1016/j.antiviral.2016.11.015.
  8. McDonagh P, Sheehy PA, Fawcett A, Norris JM. Antiviral effect of mefloquine on feline calicivirus in vitro. Vet Microbiol. 2015 Apr 17; 176 (3–4): 370–7. DOI: 10.1016/j.vetmic.2015.02.007.
  9. Fan HH, Wang LQ, Liu WL, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl). 2020 May 5; 133 (9): 1051–6. DOI: 10.1097/ CM9.0000000000000797.
  10. Filin KN, Berzin IA, Bykov VN, Gladkih VD, Loginova SYa, Savenko SV, Shhukina VN. Jeksperimental'naja ocenka aktivnosti preparata meflohin v otnoshenii koronavirusa SARS-Cov-2. Medicina jekstremal'nyh situacij. 2020; 3: 13–18. DOI: 10.47183/ mes.2020.006. Russian.
  11. Ferreira MVD, Vieira JLF, Almeida ED, et al. Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. Malar J. 2018 Jul 16; 17 (1): 268. DOI: 10.1186/s12936-018-2416-0.
  12. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID 19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar–Apr; 34: 101663. DOI: 10.1016/j. tmaid.2020.101663.
  13. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun; 57: 279–83. DOI: 10.1016/j.jcrc.2020.03.005.
  14. Vremennye metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versija 5 (08.04.20). Moskva: Ministerstvo zdravoohranenija Rossijskoj Federacii. Available from: https://static-1.rosminzdrav.ru/system/ attachments/attaches/000/049/951/original/09042020_MR_ COVID-19_v5.pdf. Russian.
  15. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020 Jul; 92 (7): 776–85. DOI: 10.1002/jmv.25898.
  16. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14; 369: m1849. DOI: 10.1136/bmj.m1849.
  17. WHO Solidarity Trial Consortium, Pan H, Peto R, HenaoRestrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. 2021; 384 (6): 497–511. DOI: 10.1056/NEJMoa2023184.
  18. Axfors C, Schmitt AM, Janiaud P, Vant Hooft J, Abd-Elsalm S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative metaanalysis of randomized trials. Nat Commun. 2021. 12 (1): 2349. DOI: 10.1038/s41467-021-22446-z.
  19. Li R, Yin K, Zhang K, Wang YY, Wu QP, Tang SB, Cheng JD. Application Prospects of Virtual Autopsy in Forensic Pathological Investigations on COVID-19. Fa Yi Xue Za Zhi. 2020 Apr; 36 (2): 149–56. DOI: 10.12116/j.issn.1004-5619.2020.02.001.
  20. Filin KN, Bykov VN, Gladkikh VD, Lugovik IA, Grebenyuk AN. Evaluation of toxicity and effectiveness of the anti-malaria preparation mefloquine with respect to SARS-CoV-2 in experiments on animals. Toxicological Review. 2021; (3): 44–49. DOI: 10.36946/0869-7922-2021-29-3-44-49. Russian.